Clinical Trials

Sponsor: Exelixis, Inc.

Sponsor Study ID: XL092-001

Study Title: A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

NCT Number: NCT03845166

Phase: I

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Bladder, Breast, Kidney, Prostate

Study Objectives: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

For more information about the trial above please contact the study team:

Principal Investigator, Theodore Gourdin, at gourdith@musc.edu.
Study Coordinator, Carly Fecio, at fecio@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)